
Medical management of overweight and obesity

Review management options based on evaluation of BMI and medical history



Assess for weight-related complications

Evaluate patients with overweight or obesity for the presence of weight-related complications including:

- CVD
- MASLD
- PCOS
- Osteoarthritis
- Prediabetes
- Obstructive sleep apnea
- Metabolic syndrome
- Type 2 diabetes
- Dyslipidemia
- Hypertension
- Female infertility
- Male hypogonadism

- Asthma/reactive airway disease
- Osteoarthritis
- Urinary stress incontinence
- GERD
- Depression

Correspondingly, patients that present with the comorbidities listed above should also be evaluated for overweight or obesity.

Management based on clinical judgement

Obesity management requires a multidisciplinary and multimodal approach to help patients achieve and maintain weight loss.

Lifestyle modifications should be

individualized and



Pharmacotherapy as an adjunct to lifestyle modifications

for patients with obesity

are insufficient or

 $(BMI \ge 30 \text{ kg/m}^2)$ or overweight

• Have weight-related complications

if lifestyle modifications alone

Fail to achieve sufficient weight

loss or experience weight regain with lifestyle interventions alone.

(BMI of 27-29.9 kg/m²), who:

Bariatric surgery

in those with severe obesity (BMI of \geq 40 kg/m²) without coexisting medical problems and the procedure would not be associated with excessive risk or those with a BMI of \geq 35 kg/m² and 1 or more severe obesityrelated complication.

consist of three components: a meal plan, physical activity, and behavioral interventions. Creating an energy deficit should be a component of developing healthy meal plans. Consider personal and cultural preferences and physical limitations.



AACE/ACE recommendations for management of obesity

Diagnostic criteria	BMI	Management based on clinical judgement
Primary Normal weight (No obesity)	< 25 kg/m ²ª	Healthy lifestyle: • Healthy meal plan • Physical activity • Health education • Built environment
Secondary Overweight stage 0 (No complications)	25-29.9 kg/m² ʰ	Lifestyle modifications: • Reduced-calorie healthy meal plan • Physical activity • Behavioral interventions
Obesity stage 0 (No complications)	≥ 30 kg/m ²¢	 Lifestyle (reduced-calorie healthy meal plan, physical activity, behavioral interventions) Consider pharmacotherapy as appropriate if lifestyle modification alone not effective (BMI ≥27 kg/m²)
Tertiary Obesity stage 1 (1 or more mild-moderate complications ^d)	≥ 25 ^b	 Lifestyle (reduced-calorie healthy meal plan, physical activity, behavioral interventions) Consider pharmacotherapy as appropriate with lifestyle intervention (BMI ≥27 kg/m²)
Obesity stage 2 (at least 1 severe complication ^e)	≥ 25 kg/m ²ª	 Lifestyle (reduced-calorie healthy meal plan, physical activity, behavioral interventions) Add pharmacotherapy as appropriate with lifestyle intervention (BMI ≥27 kg/m²) Consider bariatric surgery as appropriate (BMI ≥35 kg/m²)

^aCutoff point of 23 kg/m² for certain ethnicities. ^b23-24.9 kg/m² in certain ethnicities. ^c≥25 in certain ethnicities. ^dOr who are being treated effectively with moderate weight loss. ^eOr who requires more significant weight loss for effective treatment.

Once the initial plateau for weight loss has been achieved, re-evaluate the weight-related complications. If the complications have not been managed to target, weight-loss therapy should be intensified, or complication-specific interventions need to be initiated.

Since obesity is a chronic disease and the diagnostic categories for obesity may not be static, patients require ongoing follow-up, re-evaluation and long-term treatment.

AACE=American Association of Clinical Endocrinologists; ACE=American College of Endocrinology; BMI=body mass index.

Reference: Garvey WT, Mechanick JI, Brett EM, et al. American Association of Clinical Endocrinologists and American College of Endocrinology comprehensive clinical practice guidelines for medical care of patients with obesity. *Endocr Pract.* 2016;22(suppl 3):1-203.



Visit novoMEDLINK.com for additional resources for you and your patients with obesity.

novoMEDLINK[™] is a trademark of Novo Nordisk A/S. Novo Nordisk is a registered trademark of Novo Nordisk A/S. © 2025 Novo Nordisk All rights reserved. US25OB00311 June 2025 For Health Care Professionals $\mathsf{NOVOMEDLINK}^{\mathbb{N}}$ >

